| Issuer | % of Class | Filed |
|---|---|---|
|
Arbutus Biopharma Corp
13D/A
Amendment 14
ABUS · 03879J100
|
19.5% |
10/5/2026
Event 10/1/2026
|
|
Immunovant, Inc.
13D/A
Amendment 10
IMVT · 45258J102
|
55.9% |
12/12/2025
Event 12/12/2025
|
|
Immunovant, Inc.
13D/A
Amendment 9
IMVT · 45258J102
|
56.9% |
4/21/2025
Event 4/21/2025
|
|
Arbutus Biopharma Corp
13D/A
Amendment 13
ABUS · 03879J100
|
20.5% |
2/25/2025
Event 2/21/2025
|
|
Arbutus Biopharma Corp
13D/A
Amendment 12
ABUS · 03879J100
|
20.5% |
2/18/2025
Event 2/18/2025
|
|
Immunovant, Inc.
13D/A
Amendment 8
IMVT · 45258J102
|
56.9% |
1/15/2025
Event 1/13/2025
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.